1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors like Vorinostat and Entinostat may encourage hair regrowth and could be new treatments for hair loss conditions.
November 2023 in “Translational Medicine Communications” Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.
Blocking the Mitochondrial Pyruvate Carrier causes stress in hair follicles, which can be reduced by an ISR inhibitor.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
2 citations
,
January 2019 in “Annals of Dermatology” Melandrium firmum extract helps mice grow hair by blocking a hair loss enzyme and changing hair growth genes.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
Developing microRNA-based treatments is hard but has potential.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
39 citations
,
March 2009 in “Dermatology Online Journal” Erlotinib can cause persistent excessive hair growth.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Derinat helps extend hair growth by reducing harmful molecules in skin cells.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
91 citations
,
April 2006 in “PubMed” EGFR-targeting cancer drugs can cause skin rashes and other side effects.